Novo Nordisk A/S’s Price-to-Sales Ratio at a glance
Novo Nordisk A/S reports price-to-sales ratio of 9.6x for Dec 2024. The prior period recorded 13.5x (Dec 2023). Year over year the metric moved −3.9 (−28.9%). The rolling three-period average stands at 11.7x. Data last refreshed Dec 7, 2025, 2:51 AM.
Latest reading
9.6x · Dec 2024
YoY movement
−3.9 (−28.9%)
Rolling average
11.7x
Current Price-to-Sales Ratio
9.6x
−3.9
−28.9%
Rolling average
11.7x
Latest Value
9.6x
Dec 2024
YoY Change
−3.9
Absolute
YoY Change %
−28.9%
Rate of change
3-Period Avg
11.7x
Smoothed
Narrative signal
Novo Nordisk A/S’s price-to-sales ratio stands at 9.6x for Dec 2024. Year-over-year, the metric shifted by −3.9, translating into a −28.9% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How price-to-sales ratio shapes Novo Nordisk A/S's story
As of Dec 2024, Novo Nordisk A/S reports price-to-sales ratio of 9.6x. Track price-to-sales multiples to contextualize revenue-driven valuation swings and peer comparisons.
When to use price-to-sales
P/S is helpful for companies with slim or volatile profits. It shows how rich investors value each dollar of revenue.
Compare against industry norms
High-growth software firms command higher P/S ratios than retailers. Stack the metric versus sector averages to read sentiment.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
84.7%
Operating Margin
44.2%
Net Profit Margin
34.8%
Return on Equity
70.4%
Return on Assets
21.7%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Novo Nordisk A/S (NVO) FAQs
Answers tailored to Novo Nordisk A/S’s price-to-sales ratio profile using the latest Financial Modeling Prep data.
What is Novo Nordisk A/S's current price-to-sales ratio?
As of Dec 2024, Novo Nordisk A/S reports price-to-sales ratio of 9.6x. This reading reflects the latest filings and price data for NVO.
How is Novo Nordisk A/S's price-to-sales ratio trending year over year?
Year-over-year, the figure shifts by −3.9 (−28.9%). Pair this context with revenue growth and free cash flow signals to gauge momentum for NVO.
Why does price-to-sales ratio matter for Novo Nordisk A/S?
Price-to-sales compares market capitalization with revenue to assess valuation against top-line performance. For Novo Nordisk A/S, operating within Healthcare — Drug Manufacturers - General, tracking this metric helps benchmark management's execution against close competitors.
Is Novo Nordisk A/S's price-to-sales ratio above its recent average?
Novo Nordisk A/S's rolling three-period average sits at 11.7x. Comparing the latest reading of 9.6x to that baseline highlights whether momentum is building or fading for NVO.
How frequently is Novo Nordisk A/S's price-to-sales ratio refreshed?
Data for NVO was last refreshed on Dec 7, 2025, 2:51 AM and updates automatically every 24 hours, keeping your valuation inputs current.